Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don Carson who wrote (84)	2/3/1999 7:42:00 PM
From: Heat Shock	Read Replies (1) of 236

To all: StressGen enters the clinic with lead product HspE7 against cervical dysplasia: newswire.ca I was delighted that the indication for the trial is cervical dysplasia. It will be a heck of a lot easier to get FDA approval for treatment of warts compared to treatment of cancer. The press release says the patient population will have CIN II and CIN III. This was somewhere on the web: CIN (cervical intraepithelial neoplasia): lesions on the epithelium of the cervix that are precursors of invasive disease. CIN II and CIN III have the potential for progressing to invasive cervical cancer; CIN I does not usually progress to invasive disease. The link below has an excellent discussion (with pictures) of the different grades of cervical dysplasia. gynalternatives.com Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next